Cargando…
Albumin-Functionalized Iron Oxide Nanoparticles for Theranostics: Engineering and Long-Term In Situ Imaging
Magnetic nanosystems (MNSs) consisting of magnetic iron oxide nanoparticles (IONPs) coated by human serum albumin (HSA), commonly used as a component of hybrid nanosystems for theranostics, were engineered and characterized. The HSA coating was obtained by means of adsorption and free radical modifi...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9782891/ https://www.ncbi.nlm.nih.gov/pubmed/36559265 http://dx.doi.org/10.3390/pharmaceutics14122771 |
_version_ | 1784857446785744896 |
---|---|
author | Bychkova, Anna V. Yakunina, Marina N. Lopukhova, Mariia V. Degtyarev, Yevgeniy N. Motyakin, Mikhail V. Pokrovsky, Vadim S. Kovarski, Alexander L. Gorobets, Maria G. Retivov, Vasily M. Khachatryan, Derenik S. |
author_facet | Bychkova, Anna V. Yakunina, Marina N. Lopukhova, Mariia V. Degtyarev, Yevgeniy N. Motyakin, Mikhail V. Pokrovsky, Vadim S. Kovarski, Alexander L. Gorobets, Maria G. Retivov, Vasily M. Khachatryan, Derenik S. |
author_sort | Bychkova, Anna V. |
collection | PubMed |
description | Magnetic nanosystems (MNSs) consisting of magnetic iron oxide nanoparticles (IONPs) coated by human serum albumin (HSA), commonly used as a component of hybrid nanosystems for theranostics, were engineered and characterized. The HSA coating was obtained by means of adsorption and free radical modification of the protein molecules on the surface of IONPs exhibiting peroxidase-like activity. The generation of hydroxyl radicals in the reaction of IONPs with hydrogen peroxide was proven by the spin trap technique. The methods of dynamic light scattering (DLS) and electron magnetic resonance (EMR) were applied to confirm the stability of the coatings formed on the surface of the IONPs. The synthesized MNSs (d ~35 nm by DLS) were intraarterially administered in tumors implanted to rats in the dose range from 20 to 60 μg per animal and studied in vivo as a contrasting agent for computed tomography. The long-term (within 14 days of the experiment) presence of the MNSs in the tumor vascular bed was detected without immediate or delayed adverse reactions and significant systemic toxic effects during the observation period. The peroxidase-like activity of MNSs was proven by the colorimetric test with o-phenylenediamine (OPD) as a substrate. The potential of the synthesized MNSs to be used for theranostics, particularly, in oncology, was discussed. |
format | Online Article Text |
id | pubmed-9782891 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-97828912022-12-24 Albumin-Functionalized Iron Oxide Nanoparticles for Theranostics: Engineering and Long-Term In Situ Imaging Bychkova, Anna V. Yakunina, Marina N. Lopukhova, Mariia V. Degtyarev, Yevgeniy N. Motyakin, Mikhail V. Pokrovsky, Vadim S. Kovarski, Alexander L. Gorobets, Maria G. Retivov, Vasily M. Khachatryan, Derenik S. Pharmaceutics Article Magnetic nanosystems (MNSs) consisting of magnetic iron oxide nanoparticles (IONPs) coated by human serum albumin (HSA), commonly used as a component of hybrid nanosystems for theranostics, were engineered and characterized. The HSA coating was obtained by means of adsorption and free radical modification of the protein molecules on the surface of IONPs exhibiting peroxidase-like activity. The generation of hydroxyl radicals in the reaction of IONPs with hydrogen peroxide was proven by the spin trap technique. The methods of dynamic light scattering (DLS) and electron magnetic resonance (EMR) were applied to confirm the stability of the coatings formed on the surface of the IONPs. The synthesized MNSs (d ~35 nm by DLS) were intraarterially administered in tumors implanted to rats in the dose range from 20 to 60 μg per animal and studied in vivo as a contrasting agent for computed tomography. The long-term (within 14 days of the experiment) presence of the MNSs in the tumor vascular bed was detected without immediate or delayed adverse reactions and significant systemic toxic effects during the observation period. The peroxidase-like activity of MNSs was proven by the colorimetric test with o-phenylenediamine (OPD) as a substrate. The potential of the synthesized MNSs to be used for theranostics, particularly, in oncology, was discussed. MDPI 2022-12-11 /pmc/articles/PMC9782891/ /pubmed/36559265 http://dx.doi.org/10.3390/pharmaceutics14122771 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Bychkova, Anna V. Yakunina, Marina N. Lopukhova, Mariia V. Degtyarev, Yevgeniy N. Motyakin, Mikhail V. Pokrovsky, Vadim S. Kovarski, Alexander L. Gorobets, Maria G. Retivov, Vasily M. Khachatryan, Derenik S. Albumin-Functionalized Iron Oxide Nanoparticles for Theranostics: Engineering and Long-Term In Situ Imaging |
title | Albumin-Functionalized Iron Oxide Nanoparticles for Theranostics: Engineering and Long-Term In Situ Imaging |
title_full | Albumin-Functionalized Iron Oxide Nanoparticles for Theranostics: Engineering and Long-Term In Situ Imaging |
title_fullStr | Albumin-Functionalized Iron Oxide Nanoparticles for Theranostics: Engineering and Long-Term In Situ Imaging |
title_full_unstemmed | Albumin-Functionalized Iron Oxide Nanoparticles for Theranostics: Engineering and Long-Term In Situ Imaging |
title_short | Albumin-Functionalized Iron Oxide Nanoparticles for Theranostics: Engineering and Long-Term In Situ Imaging |
title_sort | albumin-functionalized iron oxide nanoparticles for theranostics: engineering and long-term in situ imaging |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9782891/ https://www.ncbi.nlm.nih.gov/pubmed/36559265 http://dx.doi.org/10.3390/pharmaceutics14122771 |
work_keys_str_mv | AT bychkovaannav albuminfunctionalizedironoxidenanoparticlesfortheranosticsengineeringandlongterminsituimaging AT yakuninamarinan albuminfunctionalizedironoxidenanoparticlesfortheranosticsengineeringandlongterminsituimaging AT lopukhovamariiav albuminfunctionalizedironoxidenanoparticlesfortheranosticsengineeringandlongterminsituimaging AT degtyarevyevgeniyn albuminfunctionalizedironoxidenanoparticlesfortheranosticsengineeringandlongterminsituimaging AT motyakinmikhailv albuminfunctionalizedironoxidenanoparticlesfortheranosticsengineeringandlongterminsituimaging AT pokrovskyvadims albuminfunctionalizedironoxidenanoparticlesfortheranosticsengineeringandlongterminsituimaging AT kovarskialexanderl albuminfunctionalizedironoxidenanoparticlesfortheranosticsengineeringandlongterminsituimaging AT gorobetsmariag albuminfunctionalizedironoxidenanoparticlesfortheranosticsengineeringandlongterminsituimaging AT retivovvasilym albuminfunctionalizedironoxidenanoparticlesfortheranosticsengineeringandlongterminsituimaging AT khachatryandereniks albuminfunctionalizedironoxidenanoparticlesfortheranosticsengineeringandlongterminsituimaging |